Simeon George, SR One CEO
May 23, 2024 10:32 AM EDT
Financing

Ex­clu­sive: SR One rais­es $200M+ for third fund, still with GSK sup­port

Kyle LaHucik

Senior Reporter

SR One, a life sci­ences ven­ture cap­i­tal firm that years ago split from GSK, has raised more than $200 mil­lion for a growth op­por­tu­ni­ties fund …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

With new da­ta, As­traZeneca makes the case for its BTK in­hibitor in a first-line set­ting

Nurix’s pro­tein de­grad­er over­comes re­sis­tance to BTK mu­ta­tions in small leukemia study

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times